Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017

E. E. Roberts; S. Nowsheen; M. D.P. Davis; M. T. McEvoy; C. C. Newman; J. C. Sartori Valinotti; G. F. Sciallis; R. R. Torgerson; D. A. Wetter

doi:10.1111/jdv.16302

Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017

E. E. Roberts, S. Nowsheen, M. D.P. Davis, M. T. McEvoy, C. C. Newman, J. C. Sartori Valinotti, G. F. Sciallis, R. R. Torgerson, D. A. Wetter

Dermatology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Background: Few large studies have assessed spironolactone treatment of adult female acne. Objectives: To explore the role of spironolactone in the treatment of adult female acne. Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017. Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two-thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long-term treatment with spironolactone (median duration, 13 months) and had few adverse effects. Conclusions: Spironolactone is a safe and effective treatment of acne for women.

Original language	English (US)
Pages (from-to)	2106-2110
Number of pages	5
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	34
Issue number	9
DOIs	https://doi.org/10.1111/jdv.16302
State	Published - Sep 1 2020

ASJC Scopus subject areas

Dermatology
Infectious Diseases

Access to Document

10.1111/jdv.16302

Cite this

Roberts, E. E., Nowsheen, S., Davis, M. D. P., McEvoy, M. T., Newman, C. C., Sartori Valinotti, J. C., Sciallis, G. F., Torgerson, R. R., & Wetter, D. A. (2020). Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017. Journal of the European Academy of Dermatology and Venereology, 34(9), 2106-2110. https://doi.org/10.1111/jdv.16302

Roberts, EE, Nowsheen, S, Davis, MDP, McEvoy, MT, Newman, CC, Sartori Valinotti, JC, Sciallis, GF, Torgerson, RR & Wetter, DA 2020, 'Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017', Journal of the European Academy of Dermatology and Venereology, vol. 34, no. 9, pp. 2106-2110. https://doi.org/10.1111/jdv.16302

@article{f5b0980d6d3741b4abbbdaac0f52b760,

title = "Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017",

abstract = "Background: Few large studies have assessed spironolactone treatment of adult female acne. Objectives: To explore the role of spironolactone in the treatment of adult female acne. Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017. Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two-thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long-term treatment with spironolactone (median duration, 13 months) and had few adverse effects. Conclusions: Spironolactone is a safe and effective treatment of acne for women.",

author = "Roberts, {E. E.} and S. Nowsheen and Davis, {M. D.P.} and McEvoy, {M. T.} and Newman, {C. C.} and {Sartori Valinotti}, {J. C.} and Sciallis, {G. F.} and Torgerson, {R. R.} and Wetter, {D. A.}",

note = "Publisher Copyright: {\textcopyright} 2020 European Academy of Dermatology and Venereology",

year = "2020",

month = sep,

day = "1",

doi = "10.1111/jdv.16302",

language = "English (US)",

volume = "34",

pages = "2106--2110",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Treatment of acne with spironolactone

T2 - a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017

AU - Roberts, E. E.

AU - Nowsheen, S.

AU - Davis, M. D.P.

AU - McEvoy, M. T.

AU - Newman, C. C.

AU - Sartori Valinotti, J. C.

AU - Sciallis, G. F.

AU - Torgerson, R. R.

AU - Wetter, D. A.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Background: Few large studies have assessed spironolactone treatment of adult female acne. Objectives: To explore the role of spironolactone in the treatment of adult female acne. Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017. Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two-thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long-term treatment with spironolactone (median duration, 13 months) and had few adverse effects. Conclusions: Spironolactone is a safe and effective treatment of acne for women.

AB - Background: Few large studies have assessed spironolactone treatment of adult female acne. Objectives: To explore the role of spironolactone in the treatment of adult female acne. Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017. Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two-thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long-term treatment with spironolactone (median duration, 13 months) and had few adverse effects. Conclusions: Spironolactone is a safe and effective treatment of acne for women.

UR - http://www.scopus.com/inward/record.url?scp=85081235541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081235541&partnerID=8YFLogxK

U2 - 10.1111/jdv.16302

DO - 10.1111/jdv.16302

M3 - Article

C2 - 32078195

AN - SCOPUS:85081235541

SN - 0926-9959

VL - 34

SP - 2106

EP - 2110

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 9

ER -

Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this